Emerging Therapy Solutions
Overview
Emerging Therapy Solutions (ETS) is a pioneering healthcare company focused on managing risks associated with high-cost therapies for rare and complex medical conditions. Founded in 2018 and headquartered in Bloomington, Minnesota, ETS was formed by industry veterans from managed care solutions, healthcare biotech, and transplantation services. The company has raised approximately $23.3 million over multiple funding rounds, with significant investment from Telegraph Hill Partners.
Recent Developments
- April 2025: ETS attended the 18th Annual Personalized Medicine Conference, emphasizing the importance of ongoing investment in research and strategies for widening access to personalized medicine.
- December 2024: ETS partnered with ELMCRx Solutions to offer enhanced specialty savings for cell and gene therapy costs, helping businesses manage high-cost specialty claims more effectively.
- November 2024: A strategic move was made by ETS in partnering with ELMCRx to provide advanced forecasting tools, facilitating the management of financial risks associated with cell and gene therapies.
- April 2024: ETS successfully secured a $5 million investment in a Series C funding round, continuing to drive growth and innovation in therapy management solutions.
- Late 2023: Emerging Therapy Solutions enhanced their platform's capabilities, incorporating new predictive analytics features to better assist healthcare providers in managing complex therapy treatments.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | Bloomington, Minnesota |
| Founders | David J. McLean |
| Revenue | Not publicly available |
| Profits | Not publicly available |
| Key Investors | Telegraph Hill Partners |
| Industry | Healthcare/Insurance |
| Employees | Approximately 39 |
Early History
Emerging Therapy Solutions originated to address the growing complexity and cost concerns associated with cell and gene therapies. Founded by David J. McLean, the company leveraged over 30 years of experience in managing organ transplants and complex case planning to transition into the cutting-edge space of cell and gene therapies. ETS initially expanded by acquiring LifeTrac, enhancing their expertise and extending service offerings to include comprehensive management solutions for both organ transplants and new-age therapies.
Company Profile and Achievements
ETS specializes in the predictive management of cell and gene therapy treatments for healthcare payers. Their platform simplifies patient management through data collection and comprehensive analytics, enabling accurate cost forecasting and strategic planning. Key achievements include:
- Partnering with numerous healthcare payers to manage the financial risks tied to high-cost therapies effectively.
- Integrating holistic care navigation and expert physician consultations within their service offerings.
- Building a robust Centers of Excellence (COE) network to optimize patient outcomes and care costs.
- Developing a proprietary intelligence platform that enhances operational efficiencies for their clients.
Current Operations and Market Position
Emerging Therapy Solutions continues to operate at the forefront of healthcare insurance and management, positioning itself as a key player in managing complex medical therapies. ETS's current operations focus on providing strategic insights and risk management solutions, particularly in the rapidly evolving fields of cell and gene therapies. They serve a diverse clientele, including self-insured employers and large health plans, providing tailored solutions that mitigate risk and optimize therapeutic outcomes.
Conclusion
Emerging Therapy Solutions stands out in the healthcare industry for its specialized focus on managing the complexities of cell and gene therapies. With a strong foundation supported by significant funding and strategic partnerships, ETS is well-positioned to navigate the challenges of high-stakes medical therapies and play a pivotal role in shaping the future of personalized medicine. As more therapies enter mainstream healthcare, ETS's strategic foresight and comprehensive service offerings are likely to continue propelling the company's growth and influence in the industry.